362 studies found for:    Open Studies | "Multiple Sclerosis"
Show Display Options
Rank Status Study
21 Unknown  A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Avonex and Topamax
22 Recruiting EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Interventions: Device: spinal cord MRI follow-up;   Other: clinical follow-up;   Other: brain MRI follow-up
23 Recruiting Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Procedure: Multiple Sclerosis Functional Composite;   Procedure: Mobile Multiple Sclerosis Functional Composite
24 Recruiting Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
Condition: Multiple Sclerosis-Relapsing-Remitting
Intervention: Drug: Gilenya
25 Recruiting TMP001 in Relapsing-remitting Multiple Sclerosis
Condition: Remitting-Relapsing Multiple Sclerosis
Intervention: Drug: TMP001
26 Unknown  Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Other: Neuropsychological assessment
27 Recruiting A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif®
28 Unknown  A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Other: MSDX Complex-1 Biomarker test
29 Not yet recruiting A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Biological: NeuroVax;   Biological: IFA Incomplete Freund's Adjuvant
30 Not yet recruiting Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: IL2;   Drug: Placebo
31 Recruiting Natural History of Multiple Sclerosis and Its Mimickers
Conditions: Neurologic Disorders;   Healthy Volunteers;   Multiple Sclerosis
Intervention:
32 Recruiting MEsenchymal StEm Cells for Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Mesenchymal stem cells;   Drug: Suspension media
33 Recruiting Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Biological: Autologous adipose derived mesenchymal cells
34 Unknown  The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: lamotrigine
35 Recruiting Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention:
36 Recruiting Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
Condition: Pediatric Multiple Sclerosis
Intervention:
37 Unknown  Vitamine D in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Vitamin D;   Drug: Placebo
38 Recruiting Trekking Poles to Aid Multiple Sclerosis Gait Impairment
Condition: Multiple Sclerosis
Interventions: Other: No device;   Device: Single-point cane (SPC);   Device: Four-point cane (FPC);   Device: Trekking pole (TP).
39 Unknown  Cannabis for Spasticity in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Smoked Cannabis;   Drug: Smoked Cannabis and oral marinol;   Drug: Placebo
40 Recruiting Evaluation of Coagulation in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years